ArticleCureus2026
Management of No-Reflow With Intracoronary Thrombolysis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No-reflow is a recurring phenomenon during coronary angioplasty that consists of the failure to reestablish blood flow after clearing an occluded coronary artery. Several treatments have been proposed for the management of no-reflow, including intracoronary thrombolysis, which has emerged in recent years as one of the means of managing this phenomenon. We report the case of a 68-year-old female patient with a high cardiovascular risk, admitted for the management of non-ST-elevation acute coronary syndrome, who presented a no-reflow phenomenon after angioplasty of the right coronary artery. After the failure of the various means available to reopen the artery, a 30 mg dose of tenecteplase was administered intracoronary with restoration of Thrombolysis in Myocardial Infarction III flow in the angiographic control and good clinical and rhythmic evolution. Fibrinolytic agents remain an effective means in the treatment of acute coronary syndromes with ST-segment elevation. Its use in intracoronary therapy has demonstrated its benefit in restoring flow and improving microcirculation while maintaining a satisfactory safety profile. The use of these agents in the treatment of no-reflow remains an alternative to the usual treatment, such as adenosine and verapamil, and mechanical means, such as thrombo-aspiration, allowing dissolution of the thrombus and reestablishment of the flow. The management of no-reflow phenomena remains difficult, given the varied pathophysiology of this phenomenon and the therapeutic arsenal available for its management. However, intracoronary thrombolysis for the management of no-reflow remains an attractive and interesting alternative with results that remain acceptable, but which need to be approved by studies on larger samples with more details on the dose and the administration methodology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.